ICON Partners with iCardiac Technologies to Provide an Earlier and More Precise Method for Evaluating Cardiac Safety
ICON Certified as a Partner of iCardiac’s Early Precision QT® Program
Dublin, Ireland, 3rd November, 2015 – ICON plc, (NASDAQ: ICLR) a global provider of drug development solutions and services to the pharmaceutical, biotechnology and medical device industries, today announced that its clinical research unit in San Antonio is a certified and preferred site in iCardiac’s Early Precision QT Program. The certification enables ICON to offer iCardiac’s Early Precision QT® services for evaluating the cardiac safety of new compounds in Phase I clinical trials. This solution provides clients with an earlier and more precise assessment of the safety risk of their drug and potentially eliminates the need for a separate Thorough QT (TQT) study in later stages of development.